• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     NIHR Health Technology Assessment programme Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine
2013     NIHR Health Technology Assessment programme SeHCAT (Tauroselcholic [75 selenium] acid) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss
2013     NIHR Horizon Scanning Centre (NIHR HSC) Phagenyx™ for stroke-induced dysphagia
2013     NIHR Horizon Scanning Centre (NIHR HSC) AngelMed Guardian® System for detection of myocardial infarction
2013     The Regional Health Technology Assessment Centre (HTA-centrum) Endobronchial lung volume reduction in patients with severe chronic obstructive pulmonary disease
2013     NIHR Health Technology Assessment programme Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia
2013     Health Quality Ontario (HQO) Transcatheter aortic valve implantation for the treatment of aortic valve stenosis: an evidence update
2013     NIHR Horizon Scanning Centre (NIHR HSC) Prolonged release naltrexone and bupropion (Contrave) for the management of obesity
2013     NIHR Health Services and Delivery Research programme Towards equitable commissioning for our multiethnic society: a mixed-methods qualitative investigation of evidence utilisation by strategic commissioners and public health managers
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     NIHR Horizon Scanning Centre (NIHR HSC) Parachute® Implant System for ischaemic heart failure
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei]
2013     NIHR Health Technology Assessment programme Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2 positive metastatic or locally recurrent unresectable breast cancer: a single technology appraisal
2013     Health Quality Ontario (HQO) OHTAC recommendation: transcatheter aortic valve implantation for treatment of aortic valve stenosis
2013     NIHR Horizon Scanning Centre (NIHR HSC) Anamorelin for anorexia-cachexia in advanced non-small cell lung cancer
2013     NIHR Health Services and Delivery Research programme An evaluation of foundation doctor training: a mixed-methods study of the impact on workforce well-being and patient care [the Evaluating the Impact of Doctors in Training (EDiT) study]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab Vedotin - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2013     Medical Services Advisory Committee (MSAC) Capsule endoscopy for the diagnosis of suspected small bowel Crohn disease
2013     NIHR Health Technology Assessment programme Screening for type 2 diabetes: a short report for the National Screening Committee
2013     NIHR Horizon Scanning Centre (NIHR HSC) T30 neurostimulator device for chronic tonal subjective tinnitus
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or EPIC) in patients with colorectal adenocarcinoma and peritoneal carcinomatosis.]
2013     NIHR Health Technology Assessment programme Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
2013     Health Quality Ontario (HQO) Photoselective vaporization for the treatment of benign prostatic hyperplasia
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease
2013     University of York Patient safety. 10 things NHS Trusts should already be doing
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pixantrone - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of depth of anaesthesia monitoring (E-Entropy, Bispectral Index and Narcotrend): a systematic review and economic evaluation
2013     NIHR Health Technology Assessment programme Lenalidomide for the treatment of myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality
2013     Health Quality Ontario (HQO) OHTAC recommendation: photoselective vaporization for the treatment of benign prostatic hyperplasia
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     NIHR Health Technology Assessment programme Rapid fetal fibronectin (fFN) testing to predict pre-term birth in women with symptoms of premature labour: A systematic review and cost-effectiveness analysis
2013     NIHR Health Technology Assessment programme Aflibercept solution for injection for the treatment of wet age-related macular degeneration
2013     Health Quality Ontario (HQO) Optimizing chronic disease management in the community (outpatient) setting (OCDM): an evidentiary framework
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     NIHR Health Technology Assessment programme Pirfenidone for the treatment of idiopathic pulmonary fibrosis
2013     NIHR Health Technology Assessment programme Pragmatic cluster randomised trial of PhysioDirect telephone assessment and advice services for physiotherapy
2013     NIHR Health Technology Assessment programme Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy
2013     Health Quality Ontario (HQO) OHTAC recommendation: optimizing chronic disease management in the community (outpatient) setting (OCDM)
2013     Scottish Health Technologies Group (SHTG) Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective?
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Discharge planning in chronic conditions: an evidence-based analysis
2013     Institute for Clinical Evaluative Sciences (ICES) Ontario stroke evaluation report 2013: spotlight on secondary stroke prevention and care
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) In-home care for optimizing chronic disease management in the community: an evidence-based analysis
2013     Institute for Clinical Evaluative Sciences (ICES) Atlas on the primary care of adults with developmental disabilities in Ontario
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Continuity of care to optimize chronic disease management in the community setting: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (New therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Impact of advanced (open) access scheduling on patients with chronic diseases: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-16 Saxagliptin/metformin]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) Renal sympathetic denervation in patients with therapy resistant hypertension
2013     Health Quality Ontario (HQO) Screening and management of depression for adults with chronic diseases: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-15 Crizotinib]
2013     Health Quality Ontario (HQO) Self-management support interventions for persons with chronic disease: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pilot study: analytic hierarchy process in the indication "major depression"]
2013     Health Quality Ontario (HQO) Specialized nursing practice for chronic disease management in the primary-care setting: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-18 (dapagliflozin)]
2013     NIHR Health Technology Assessment programme Ivabradine for the treatment of chronic heart failure
2013     Health Information and Quality Authority (HIQA) Health technology assessment (HTA) of surveillance of women aged less than 50 years at elevated risk of breast cancer
2013     Andalusian Health Technology Assessment Area (AETSA) [Tumor treating fields therapy (TTF) for glioblastoma. A systematic review of the literature]
2013     Health Quality Ontario (HQO) Electronic tools for health information exchange: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     NIHR Health Technology Assessment programme Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema
2013     Health Quality Ontario (HQO) Health technologies for the improvement of chronic disease management: a review of the Medical Advisory Secretariat evidence-based analyses between 2006 and 2011
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer]
2013     Medical Advisory Secretariat (MAS) Transcatheter Aortic Valve Implantation (TAVI) for treatment of aortic valve stenosis: an evidence update
2013     Health Quality Ontario (HQO) Optimizing chronic disease management mega-analysis: economic evaluation
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) How diet challenges are magnified in vulnerable or marginalized people with diabetes and heart disease: a systematic review and qualitative meta-synthesis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-05 (fidaxomicin)]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Overweight and obesity: the efficacy of diets for weight maintenance after weight loss]
2013     Andalusian Health Technology Assessment Area (AETSA) [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents]
2013     Health Quality Ontario (HQO) Chronic disease patients' experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The effectiveness of occupational therapy for persons with moderate and severe dementia]
2013     Health Quality Ontario (HQO) Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lixisenatide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Agenzia nazionale per i servizi sanitari regionali (Agenas) Selective Internal Radiation Therapy (SIRT) in colorectal liver metastases
2013     Health Quality Ontario (HQO) Experiences of patient-centredness with specialized community-based care: a systematic review and qualitative meta-synthesis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-06 (Abiraterone acetate [New therapeutic indication])]
2013     Health Quality Ontario (HQO) Electrical stimulation for drug-resistant epilepsy: an evidence-based analysis
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in oesophagus cancer]
2013     Health Quality Ontario (HQO) Electrical stimulation for drug-resistant epilepsy: OHTAC recommendation
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colestilan - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Carbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: an evidence-based analysis
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluating the implementation of diagnostic telemedicine in the field of dermatology]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Saxagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Carbon-13 urea breath test for Helicobacter pylori infection in patients with uninvestigated ulcer-like dyspepsia: OHTAC recommendation
2013     Basque Office for Health Technology Assessment (OSTEBA) [Usefulness of dietary treatments in Lysine metabolic disorders]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Technology and Policy Unit (HTPU) Level I and level III sleep studies for the diagnosis of sleep disordered breathing (SDB) in adults
2013     Health Quality Ontario (HQO) Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis
2013     Medical Services Advisory Committee (MSAC) Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
2013     Basque Office for Health Technology Assessment (OSTEBA) [Lipid metabolism disorders: review of the indications of fat free dietetic products and nutritional alternatives with regularly consumed foodstuffs]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sitagliptin/Metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Hysteroscopic tubal sterilization: an evidence-based analysis
2013     Basque Office for Health Technology Assessment (OSTEBA) [Economic evaluation of a telemonitoring intervention from primary care in home care patients with cardiac insufficiency and/or chronic bronchial disorders: Cost-effectiveness analysis, TELBIL study]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Health Quality Ontario (HQO) Hysteroscopic tubal sterilization: OHTAC recommendation